Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00008255 · ClinicalTrials.gov registry record · Phase 2
INS316 in Diagnosing Lung Cancer in Patients With Untreated Lung Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00008255: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00008255 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00008255, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Doctors can diagnose lung cancer by collecting mucus coughed up from the lungs and examining it under a microscope to look for cancer cells. Breathing in INS316 may make it easier for patients to cough up mucus. PURPOSE: Randomized phase II trial to study the effectiveness of INS316 in helping to diagnose lung cancer.
Interventions
- OTHER sputum cytology
- DRUG INS316
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-08 |
| Est. Completion | 2004-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00008255
The ClinicalTrials.gov registry entry for NCT00008255 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sputum cytology is the first listed.
NCT00008255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00008255 about?
NCT00008255 is a clinical study titled "INS316 in Diagnosing Lung Cancer in Patients With Untreated Lung Cancer". RATIONALE: Doctors can diagnose lung cancer by collecting mucus coughed up from the lungs and examining it under a microscope to look for cancer cells. Breathing in INS316 may make it easier for patients to cough up mucus. PURPOSE: Randomized phase II trial to study the effectiveness of INS316 in h...
What is the current status of trial NCT00008255?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-08. Estimated completion is 2004-05.
What interventions are being tested in trial NCT00008255?
The interventions under investigation include: sputum cytology (OTHER), INS316 (DRUG).
Who is sponsoring clinical trial NCT00008255?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.